|Bid||14.40 x 900|
|Ask||14.45 x 900|
|Day's Range||14.35 - 14.95|
|52 Week Range||5.10 - 16.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.33|
W.W. Grainger (GWW) will gain from its investment in e-commerce and digital capabilities as well as executing supply chain management actions and efforts to strengthen relationships with customers.
Codexis (CDXS) delivered earnings and revenue surprises of 83.33% and 14.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Redwood City, California-based company said it had a loss of 7 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 2 cents per share. The producer of custom ...
Total revenues increase 31% to $13.5 million driven by higher R&D revenue. Phase 1 a clinical trial for CDX-6114 initiated. Conference call begins at 4:30 p.m. Eastern time today.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Codexis, Inc. (NASDAQ: CDXS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...
REDWOOD CITY, Calif., Aug. 01, 2018-- Codexis, Inc., a leading protein engineering company, announces that it will report second quarter 2018 financial results after market close on Wednesday, August 8, ...
Codexis, Inc. (CDXS), a leading protein engineering company, announces the appointment of Hicham Alaoui, Ph.D. to the newly created position of Vice President, Biotherapeutics Research & Development. The appointment brings Dr. Alaoui’s unique drug discovery skills and talents to Codexis at a pivotal time as the company expands its Biotherapeutics business and works to follow recent success in bringing its first drug candidate, CDX-6114 for potential treatment of phenylketonuria (PKU), into early clinical trials.
This randomized, double-blind, placebo-controlled Phase 1a trial is intended to evaluate the safety and tolerability of CDX-6114 in up to 32 healthy volunteers, with up to four cohorts receiving a single dose of CDX-6114 at increasingly higher dose levels. Codexis also expects to generate valuable pharmacology data from this study, which will support the future development of the drug candidate.
LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on CLVS sign up now at www.wallstequities.com/registration. On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories.
The world's top lithium producer, a biotech just hitting its stride, and America's top consumer lawn care specialist should be enticing for growth-seeking investors.
Tesla investors have already made a lot of money, and that could continue. But these three stocks could do far better. Here's why.
NEW YORK, June 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of WPP ...
REDWOOD CITY, Calif., May 29, 2018-- Codexis, Inc., a leading protein engineering company, announces that management will present at three upcoming investment conferences:. 15 th Annual Craig-Hallum Institutional ...
On a per-share basis, the Redwood City, California-based company said it had a loss of 10 cents. Losses, adjusted for stock option expense and non-recurring costs, were 5 cents per share. The producer ...
Stock Monitor: RXi Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Codexis, Inc. (NASDAQ: CDXS ). If you want ...
Codexis, Inc. (CDXS) and Porton Pharma Solutions, Ltd. (300363.SZ) announce a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. The partnership will accelerate the creation and commercialization of new, low-cost, sustainable manufacturing processes, exploiting the benefits of biocatalysts to a growing number of the world’s small molecule pharmaceuticals.